Key result
Intraoperative redosing of cefazolin did not reduce the overall risk of surgical site infection in cardiac surgery lasting >240 minutes (OR 1.01), but significantly reduced the risk in procedures lasting >400 minutes (adjusted OR 0.44).
Why the study?
Does intraoperative redosing of cefazolin reduce the risk of surgical site infection in patients undergoing cardiac surgery?
Population
1,548 patients who underwent cardiac surgery lasting >240 min after preoperative administration of cefazolin…
Comparison
Intraoperative redosing of cefazolin vs No intraoperative redosing of cefazolin
Design
Cohort
Authors
Loading...
Redosing should not yet change practice for cardiac surgery >240 min; leaves open possible benefit in procedures >400 min.
Cohort (n=1,548)
No
Does intraoperative redosing of cefazolin reduce the risk of surgical site infection in patients undergoing cardiac surgery?
Odds Ratio: 1.01 (95% CI 0.7–1.47)
Absolute Event Rate: 9.4% vs 9.3%
Intraoperative redosing of cefazolin significantly reduces the risk of surgical site infections in cardiac surgeries lasting longer than 400 minutes.
Zanetti et al. (2001) conducted a cohort in Cardiac surgery (n=1,548). Intraoperative redosing of cefazolin vs. No intraoperative redosing was evaluated on Surgical site infection (OR 1.01, 95% CI 0.70-1.47). Intraoperative redosing of cefazolin did not reduce the overall risk of surgical site infection in cardiac surgery lasting >240 minutes (OR 1.01), but significantly reduced the risk in procedures lasting >400 minutes (adjusted OR 0.44).
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: